- Home
- EDN vs TRVI Comparison
EDN vs TRVI Comparison
Compare EDN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EDN | TRVI |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2007 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EDN | TRVI |
|---|---|---|
| Price | $33.01 | $13.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.59 |
| AVG Volume (30 Days) | 142.1K | ★ 2.1M |
| Earning Date | 08-11-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,678,118,877.00 | N/A |
| Revenue This Year | $32.93 | N/A |
| Revenue Next Year | $24.64 | N/A |
| P/E Ratio | $20.87 | ★ N/A |
| Revenue Growth | ★ 3.69 | N/A |
| 52 Week Low | $14.38 | $2.36 |
| 52 Week High | $51.69 | $14.00 |
Technical Indicators
Market Signals| Indicator | EDN | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 53.21 | 63.79 |
| Support Level | $33.65 | $12.75 |
| Resistance Level | $36.70 | $14.00 |
| Average True Range (ATR) | 2.31 | 0.78 |
| MACD | -0.38 | 0.10 |
| Stochastic Oscillator | 43.18 | 74.89 |
Price Performance
Historical ComparisonAbout EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.